hairlossClascoterone is a topical drug that blocks the androgen receptor in the hair follicle, so DHT can't deliver its "shrink" signal there. In two large phase 3 trials in men with mild to moderate pattern hair loss, a 5% scalp solution grew more hair than an inactive solution and kept working through 12 months. As of November 2026 it is not approved for hair loss anywhere, full results have not been published in a peer-reviewed journal, and the sponsor says it plans to file with the FDA in early 2027.
Most coverage stops at the headline "539%" figure. This article does three things the press releases don't: it explains what that number can and can't tell you, walks through the 12-month withdrawal design (the most useful part of the data), and compares the scalp dose with the dose of the clascoterone acne cream already on the market, because that comparison is where the open safety questions sit.
How clascoterone differs from finasteride and minoxidil
Pattern hair loss (androgenetic alopecia) happens when dihydrotestosterone binds to androgen receptors in genetically sensitive follicles and gradually miniaturizes them. Our explainer on DHT and hair loss covers the background.
The current medicines act at different points:
- Finasteride lowers DHT production throughout the body by blocking the 5-alpha-reductase enzyme.
- Minoxidil doesn't touch hormones; it prolongs the growth phase of the hair cycle. (See our minoxidil FAQ.)
- Clascoterone leaves DHT levels alone and instead competes with DHT for the receptor itself, where it's applied.
The appeal is blocking DHT's effect at the scalp without lowering hormones elsewhere, which is the trade-off that makes some men reluctant to take an oral DHT blocker. The molecule itself isn't new: a 1% clascoterone cream has been FDA-approved for acne since 2020.
What the phase 3 trials actually did
The two pivotal studies, SCALP 1 (NCT05910450) and SCALP 2 (NCT05914805), were identically designed and together enrolled 1,465 men at 51 sites in the US and Europe, according to Dermatology Times' report of the 12-month results. They ran in two parts:
- Months 0 to 6: men were randomly assigned to clascoterone 5% solution or an identical inactive solution (the "vehicle"), applied twice daily, double-blind.
- Months 6 to 12: men who had responded to clascoterone were re-randomized either to keep using it or to switch, without knowing, to the vehicle.
The main measure was target-area hair count (TAHC): hairs counted in a small, marked patch of scalp from standardized close-up photos. That's an objective measure, but it describes one defined patch, not the whole head, and it doesn't directly tell you how much fuller someone looks in the mirror.
Who was studied matters too: adult men with mild to moderate loss. Men with extensive baldness (higher Norwood stages) and women were not part of the phase 3 program, so the results can't be assumed to apply to them.
What "539%" does and doesn't mean
The topline results, announced in December 2025, reported a 539% relative improvement in hair count versus vehicle in SCALP 1 and 168% in SCALP 2, with side effects similar to vehicle (Practical Dermatology).
A relative improvement compares the drug group's gain with the vehicle group's gain. When the vehicle group changes very little, even a modest absolute gain in the drug group produces a huge percentage. This purely hypothetical arithmetic (not trial data) shows the effect:
| Hypothetical scenario | Vehicle group gain | Drug group gain | Relative improvement |
|---|---|---|---|
| A | +5 hairs | +32 hairs | about 540% |
| B | +10 hairs | +27 hairs | about 170% |
Scenario B has the far smaller percentage even though the drug group's absolute gain is similar. So the gap between 539% and 168% in two identically designed trials doesn't necessarily mean the drug worked three times better in one of them; it may largely reflect what happened in the vehicle groups. The sponsor's exact calculation isn't public, and neither are the absolute hair counts, so nobody outside the company can yet say how many hairs the average man gained. That is the most important missing number.
The 12-month data: the part worth paying attention to
The extension phase answers a practical question: what happens if you stop? Men who stayed on clascoterone for the full year kept gaining hair from month 3 through month 12, and their improvement was reported as 2.39-fold greater than in men switched to vehicle at six months (Dermatology Times, April 2026). Some later coverage has described that figure differently, one more reason to wait for the full publication.
The plain-English reading: clascoterone behaves like every other medical treatment for pattern hair loss. It works while you use it, and the benefit fades when you stop. A short course that permanently fixes the problem is not what this data shows.
The dose question few people are asking
Clascoterone is often described as having "no systemic absorption." The approved acne cream's own prescribing information is more nuanced, and the doses are worth comparing.
- The acne cream is labeled at about 1 gram of 1% cream twice daily, roughly 10 mg of clascoterone per application, or about 20 mg a day (US prescribing information).
- The sponsor's pipeline page says a 75 mg twice-daily dose was selected for phase 3. If that refers to the amount of clascoterone applied, it's about 150 mg a day.
On that reading, the scalp regimen delivers roughly seven times the labeled daily acne dose. In the acne cream's maximal-use study, adults applied a mean of about 6 grams twice daily for two weeks (roughly 120 mg a day), and suppression of the hypothalamic-pituitary-adrenal (HPA) axis, the body's cortisol system, appeared in 1 of 20 adults and 2 of 22 adolescents. All returned to normal within four weeks of stopping. The label lists HPA-axis suppression as a warning and notes that shifts to elevated potassium were seen in 5% of clascoterone-treated participants versus 4% on vehicle.
Two caveats keep this in proportion. Absorption depends on the formulation and the skin it's applied to, so a scalp solution and a facial cream at the same milligram dose may not behave the same way. And the hair-loss trials reported no significant systemic hormonal side effects over 12 months, while earlier phase 2 work summarized in a 2019 Journal of the American Academy of Dermatology abstract also described minimal systemic exposure. This isn't a red flag. It's a reason to want the full adrenal and potassium data published, and a reason regulators will look closely at them, because this is a drug meant to be used for decades.
What about women?
Women are a natural audience for a topical anti-androgen, but the evidence is thin. A phase 2 study in women in Germany compared 5% and 7.5% clascoterone with 2% minoxidil and vehicle (EU trial record). In the company's announcement of the results, only the subgroup of women under 30 using the 5% solution showed a statistically significant change in hair count from baseline at six months. That's not enough to support use. The acne cream's label also describes birth defects in animal studies at high exposures, so pregnancy is a real consideration. Women with thinning hair have established options, covered in our guide to female hair loss.
Can you get it now?
Not as an approved hair-loss medicine. As of November 2026 the sponsor has said it plans a US filing in early 2027, and a standard FDA review typically runs about a year after filing. Some clinics describe off-label scalp use of the acne cream, which is a different formulation and strength from the solution tested in the trials, with no published evidence on whether it works for hair. If you're considering it, discuss it with a dermatologist who can weigh it against approved options and decide what monitoring makes sense.
FAQ
Is clascoterone better than finasteride?
There's no head-to-head trial, so no one can say. Clascoterone's possible advantage is acting locally rather than lowering body-wide DHT; whether it grows as much hair is unknown until absolute results are published.
Can it be combined with minoxidil?
The mechanisms differ, so combination therapy is a logical question, but the phase 3 trials tested clascoterone on its own. Combination use hasn't been studied in published trials.
Will it help if I'm already very bald?
Probably not much. Like other DHT-targeted treatments, it acts on follicles that are shrinking but still alive. Areas bald for years generally don't respond to medication, which is where options like hair transplantation enter the discussion.
Wondering where a new treatment fits for you? Ask Hairloss.org, or browse more research write-ups in Hairloss Labs.